RT Journal Article
SR Electronic
A1 Mosley, Mary
T1 Active Maintenance Therapy Prolongs TFS and PFS in CRC
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 22
SP 15
OP 15
DO 10.1177/155989771422011
UL http://mdc.sagepub.com/content/14/22/15.1.abstract
AB One of the current standards of care for the first-line therapy of metastatic colorectal cancer (mCRC) is combination chemotherapy with fluoropyrimidine (FP) and oxaliplatin (OX) plus the angiogenesis inhibitor, bevacizumab (BEV). The Phase 3 AIO KRK 0207 study [NCT00973609] showed that active maintenance therapy with FP+BEV or BEV alone, compared with no treatment, prolonged the time-to-failure of strategy and progression-free survival in patients with mCRC after induction treatment [Arnold D et al. Ann Oncol. 2014 (abstr O-0027); J Clin Oncol. 2014 (abstr 3503)].